BRIEFING

 Curcuminoids Capsules. This proposal is based on the version of the monograph official as of May 1, 2023.

 The Dietary Supplements Admission Evaluation Expert Committee conducted an evaluation of available evidence and issued an updated assessment of turmeric-derived ingredients and recommended inclusion of the following caution label statement: Dosage forms prepared with this article should bear the following statement: "Liver problems have been reported very rarely in people taking supplements containing turmeric and/or curcuminoids. Consult your healthcare practitioner before using this product if you have a history of liver problems. Stop using this product if you develop symptoms such as abdominal pain, dark urine, or jaundice (yellowing of the skin or eyes), and seek medical advice."

 Additionally, minor editorial changes have been made to update the monograph to current USP style.

 The comment period for this revision ends on January 31, 2027. In the absence of any significant adverse comments, it is proposed to implement this revision via an Interim Revision Announcement with an official date of July 1, 2027.

 (BDSHM: A. Bzhelyansky)

 Case ID—SUB-3419